The author of that SA article sounded like an amateur, but that isn’t a surprise with SA.
My best guess would be that the US institutional investors get tapped next. They set up that avenue last year.
I also beleive this because SI has indicated that he doesn’t want to partner the paediatric aGVHD program- which is what the phase 3 trial was for.
Instead he wants to partner the adult aGVHD, class 2/3 CHF (not class 4), RA and chronic lower back pain programs.
There does appear to be a strong shift in sentiment after the phase 3 success though, so you could be right- that may be the catalyst to CHF or chronic lower back pain getting over the line.
So I would be very happy to be proven wrong
Cell Therapy News/Articles, page-158
-
- There are more pages in this discussion • 17,626 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
98.0¢ |
Change
-0.010(1.01%) |
Mkt cap ! $1.118B | |||
| Open | High | Low | Value | Volume |
| $1.00 | $1.01 | 98.0¢ | $4.720M | 4.751M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 171759 | 98.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.0¢ | 16000 | 1 |
View Market Depth
| Last trade - 16.10pm 25/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |